Garry Walsh

Medicine & Life Sciences

1. Asthma 100%
2. Eosinophils 71%
3. Interleukin-5 43%
4. levocetirizine 33%
5. Histamine Antagonists 31%
6. Epithelial Cells 30%
7. reslizumab 27%
8. Biological Products 23%
9. Cytokines 22%
10. Chronic Obstructive Pulmonary Disease 21%
11. Histamine H1 Receptors 21%
12. Inflammation 20%
13. Therapeutics 20%
14. Interleukin-13 19%
15. Interleukin-4 18%
16. montelukast 17%
17. Anti-Inflammatory Agents 17%
18. mepolizumab 16%
19. Cetirizine 16%
20. Nose 15%
21. Allergic Rhinitis 13%
22. Antibodies, Monoclonal, Humanized 13%
23. Chemokines 12%
24. Biological Therapy 12%
25. Phenotype 12%
26. Granulocyte-Macrophage Colony-Stimulating Factor 11%
27. Hydroxymethylglutaryl-CoA Reductase Inhibitors 11%
28. Child 11%
29. Eosinophilic Esophagitis 11%
30. Monoclonal Antibodies 10%
31. tralokinumab 10%
32. Interleukin-8 9%
33. Sputum 9%
34. Pharmaceutical Preparations 9%
35. pilsicainide 8%
36. Newborn Infant 8%
37. canakinumab 8%
38. Vascular Cell Adhesion Molecule-1 7%
39. Cryopyrin-Associated Periodic Syndromes 7%
40. Pyroglyphidae 7%
41. Lung 7%
42. Interleukin-10 7%
43. Fluvastatin 7%
44. Interleukin-6 6%
45. Clinical Trials 6%
46. Interleukin-1 6%
47. Lovastatin 6%
48. Biomarkers 6%
49. Pediatrics 6%
50. Leukotriene Antagonists 6%